121 related articles for article (PubMed ID: 29159556)
1. Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus.
Hu H; Chen E; Li Y; Zhu X; Zhang T; Zhu X
Biol Trace Elem Res; 2018 Aug; 184(2):391-397. PubMed ID: 29159556
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
[TBL] [Abstract][Full Text] [Related]
3. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
4. [Effect of CD40 siRNA on inflammatory response of MRL/Lpr mice].
Wang ZH; Zhang W; Zhang YQ; Pang CY; Wang YF
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):771-776. PubMed ID: 27752154
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
Mishra N; Reilly CM; Brown DR; Ruiz P; Gilkeson GS
J Clin Invest; 2003 Feb; 111(4):539-52. PubMed ID: 12588892
[TBL] [Abstract][Full Text] [Related]
6. [Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice].
Xia XR; Lin SX; Zhou Y
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):138-41. PubMed ID: 17345664
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
8. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition.
Garcia BA; Busby SA; Shabanowitz J; Hunt DF; Mishra N
J Proteome Res; 2005; 4(6):2032-42. PubMed ID: 16335948
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
Hu N; Long H; Zhao M; Yin H; Lu Q
Scand J Rheumatol; 2009; 38(6):464-71. PubMed ID: 19922023
[TBL] [Abstract][Full Text] [Related]
10. An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential.
Hadj-Slimane R; Chelbi-Alix MK; Tovey MG; Bobé P
J Interferon Cytokine Res; 2004 Dec; 24(12):717-28. PubMed ID: 15684739
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Bobé P; Bonardelle D; Benihoud K; Opolon P; Chelbi-Alix MK
Blood; 2006 Dec; 108(13):3967-75. PubMed ID: 16926289
[TBL] [Abstract][Full Text] [Related]
12. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
13. Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells.
Zhao Y; Mu Z; Cai L; Liu X; Jia J; Zhang J
Dermatol Ther; 2019 Jul; 32(4):e12849. PubMed ID: 30707471
[TBL] [Abstract][Full Text] [Related]
14. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.
Takahashi S; Fossati L; Iwamoto M; Merino R; Motta R; Kobayakawa T; Izui S
J Clin Invest; 1996 Apr; 97(7):1597-604. PubMed ID: 8601623
[TBL] [Abstract][Full Text] [Related]
15. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B lymphocyte-induced maturation protein-1 reduces the production of autoantibody and alleviates symptoms of systemic lupus erythematosus.
Luo J; Niu X; Zhang M; Zhang K; Chen M; Deng S
Autoimmunity; 2015 Mar; 48(2):80-6. PubMed ID: 25347333
[TBL] [Abstract][Full Text] [Related]
18. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus.
Yang J; Chu Y; Yang X; Gao D; Zhu L; Yang X; Wan L; Li M
Arthritis Rheum; 2009 May; 60(5):1472-83. PubMed ID: 19404966
[TBL] [Abstract][Full Text] [Related]
19. CD4(+)B220(+)TCRγδ(+) T cells produce IL-17 in lupus-prone MRL/lpr mice.
Qiu F; Li T; Zhang K; Wan J; Qi X
Int Immunopharmacol; 2016 Sep; 38():31-9. PubMed ID: 27235595
[TBL] [Abstract][Full Text] [Related]
20. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice.
Prud'homme GJ; Kono DH; Theofilopoulos AN
Mol Immunol; 1995 May; 32(7):495-503. PubMed ID: 7783752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
